Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine 2001 September;45(3) > The Quarterly Journal of Nuclear Medicine 2001 September;45(3):269-73

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rivista di Medicina Nucleare e Imaging Molecolare


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413


eTOC

 

  PET IN ONCOLOGY
Guest Editor: I. Carrio


The Quarterly Journal of Nuclear Medicine 2001 September;45(3):269-73

Copyright © 2009 EDIZIONI MINERVA MEDICA

lingua: Inglese

Evaluation of treatment response in patients with lymphoma using [18F]FDG-PET: differences between Non-Hodgkin’s Lymphoma and Hodgkin’s disease

Spaepen K., Mortelmans L.

From the Depart­ment of ­Nuclear Med­i­cine Uni­ver­sity Hos­pi­tals Gas­thuis­berg and Cath­olic Uni­ver­sity of ­Leuven, ­Leuven, Bel­gium


Full text temporaneamente non disponibile on-line. Contattaci  


Flu­o­rine-18flu­o­rod­e­ox­y­glu­cose posi­tron emis­sion tomog­raphy ([18F]FDG-PET) has ­become a ­very ­useful tech­nique for the ­therapy mon­i­toring of ­patients ­with lym­phoma. It pro­vides ­unique infor­ma­tion ­about the meta­bolic ­behavior of the dis­ease inde­pen­dent of mor­pho­log­ical cri­teria. In ­recent ­years, [18F]FDG-PET has ­proven to be a tech­nique ­with ­high sen­si­tivity for the detec­tion of ­residual ­tumor. There­fore, [18F]FDG-PET ­seems to be the ­ideal ­tool for the eval­u­a­tion of treat­ment ­response. How­ever, ­most ­recent pub­lished ­studies ­included ­both HD and NHL, ­although [18F]FDG-PET ­scan ­results in ­Hodgkin’s dis­ease (HD) has a dif­ferent ­impact ­than in Non ­Hodgkin’s Lym­phoma (NHL). In ­this ­paper, we sum­marize our find­ings on the ­role of [18F]FDG-PET in the ­therapy eval­u­a­tion of lym­phoma ­patients in a ­large ­group of ­patients and high­light the dif­fer­ences ­between the inter­pre­ta­tions of the ­results of HD and NHL ­patients. ­Finally, a ­strategy for the imple­men­ta­tion of [18F]FDG-PET in the man­age­ment of lym­phoma ­patients is pro­posed.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail